Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 May;13(7):575-84.
doi: 10.4161/cbt.19772. Epub 2012 May 1.

The chemopreventive and clinically used agent curcumin sensitizes HPV (-) but not HPV (+) HNSCC to ionizing radiation, in vitro and in a mouse orthotopic model

Affiliations

The chemopreventive and clinically used agent curcumin sensitizes HPV (-) but not HPV (+) HNSCC to ionizing radiation, in vitro and in a mouse orthotopic model

Stephen Tuttle et al. Cancer Biol Ther. 2012 May.

Abstract

Radiation therapy (RT) plays a critical role in the local-regional control of head and neck squamous cell carcinoma (HNSCC). However, the efficacy of RT in treating HNSCC is limited by severe normal tissue toxicity, predominantly mucositis. One pharmacological approach for increasing the clinical response to RT is the use of radiation response modifiers that preferentially sensitize tumor cells. Previously we demonstrated that curcumin, a natural plant polyphenol, increased the radiation sensitivity of HNSCC cells and that the observed sensitization was dependent on curcumin-mediated inhibition of thioredoxin reductase 1 (TxnRd1) a key cytosolic regulator of redox-dependent signaling. Here, we examined curcumin-induced radiation sensitization in HNSCC cell lines with differing HPV status and expressing different levels of TxnRd1, in vitro. The intrinsic radiation resistance of the HPV (-) cell lines was significantly higher than the HPV (+) cell lines used in our study. Notably, all of the HPV (-) cell lines expressed high levels of TxnRd1 and exhibited higher intrinsic resistance to RT. While curcumin was effective at increasing the radiation response of the resistant HPV (-) cell lines it had no effect on the HPV (+) cells. Based on these findings we employed an orthotopic, HPV (-) HNSCC tumor model in athymic nude mice to examine the effect of combining curcumin with fractionated RT, in vivo. The combination of curcumin feeding and fractionated RT had a significant effect on tumor doubling time and overall animal survival. We therefore propose that curcumin and RT should be considered as a first line treatment of HPV (-) HNSCC.

PubMed Disclaimer

Figures

None
Figure 1. TxnRd1 protein and activity levels in cells with different transformation status correlate with response to curcumin. (A) TxnRd1 protein levels were determined by immunoblot analysis in a panel of human head and neck cancer cell lines. FaDu, UPCISCC090, UPCISCC154 (both HPV+) SQ20B and JHU022. TxnRd1 level;s were also measured in the immortalized keratinocyte cell line HEK-001 and the leukoplakia derived line MSK = Leuk 1. β-Actin was used as a loading control. (B) Basal levels of whole-cell TxnRd activity was measured as nanomoles dihydrolipoate formed per milligram cell protein.
None
Figure 2. HPV- head and neck squamous carcinoma lines with TxnRd1 are sensitized to IR by curcumin. (A) Head and neck cell lines were treated with DMSO or 10 μM curcumin for 8 h followed by exposure to 0, 2, 4 or 6 Gy doses of IR. Survival was assessed by clonogenic assays. Points represent the average of a minimum of three independent experiments; bars ± SEM. Data were analyzed by pair wise comparison. * indicates a statistically significant difference in radiation sensitivity between curcumin treated and DMSO treated groups (p < 0.05). Values in boxes represent the dose modification factor observed at S.F. = 0.50. (B) Survival after a single dose of 2 Gy has been shown to predict intrinsic radiation sensitivity of tumor cells in vivo response. All HPV- HNSCC cell lines (FaDu, SQ20B and JHU-022, were significantly more resistant to 2 Gy of radiation then either HEK-001 or MSK-leuk-1 cells (*p < 0.05, t test). There was no difference in radiation sensitivity observed between the HPV+ cell lines and HEK-001 or MSK-Leuk 1. Pretreatment with curcumin, as indicated above, induced a significant increase in sensitivity in the three HPV- cell lines (* p < 0 0.05, t-test).
None
Figure 3. Growth of FaDu cells as an orthotopic intralingual model of HNSCC in nude mice and uptake of orally administered curcumin. (A) 10 μm cross-section of mouse tongue following H&E staining. (B) Immunohistochemical staining of a similar cross section for the proliferation marker Ki67. In both (A and B), the area labeled with T denotes tumor tissue; NS is normal stroma and NE is normal epithelium. (C) Uptake of curcumin into tumor tissues. Left panel shows a representative run for a tumor removed from an animal that was fed a 1% curcumin diet, (w/w) for 7 d, beginning 3 d after tumor implant. Right panel depicts a tumor-bearing mouse fed control lab chow. The peak that elutes at 40 min coincided with the peak obtained with the curcumin control. (D) Curcumin uptake was measured in three mice and the amount was determined by comparison to a curcumin standard. Error bars represent SEM values (p < 0.05; paired t-test). (E) TxnRd activity was measured in the tumor samples to insure that dietary curcumin was reaching the purported target in 3 mice fed 1% curcumin chow compared with 3 mice fed the control chow. Error bars represent SEM values (p < 0.05; paired t-test).
None
Figure 4. Effect of curcumin feeding with IR on orthotopic FaDu tumor growth was measured by bioluminescent image analysis. (A) FaDu cells transfected with CMV luciferase (FaDu-CMV-luci) were pretreated with 10 μM curcumin or DMSO for 8 h and then exposed to 0, 2, 4 or 6 Gy of radiation. Survival was measured by the clonogenic assay. The DMF = 1.42 for FaDu CMV-Luci cells, was similar to that of the parental FaDu cell line (Fig. 2A). (B) Representative image from two groups of mice taken 10 d after completing 3 fractions of 2 Gy given at 48 h intervals. Left panel: from the group fed 1% curcumin chow; right panel: mice from the control chow fed group. (C) Tumor growth rates from each group of mice (10 mice/group at start of experiment) (control diet, 1% curcumin diet, 2Gy x 3 ionizing radiation alone or curcumin + ionizing radiation) based on twice-weekly bioluminescent imaging. Error bars represent SEM values from surviving mice at time of measurement. (D) Volume doubling time was calculated froom the time of the second pre-irradiation bioluminescent image intensity, obtained on day 7. Interaction was assessed by repeated measures ANOVA (p < 0.0001). The doubling time for the combined curcumin and radiation group was significantly larger than the unirradiated and irradiated mice on the control diet, and the curcumin-fed mice without radiation the radiation only treatment. Box represents minimum and maximum values for each group of animals with the median indicated by the interior bar. Error bars represent 95% confidence limits.
None
Figure 5. Effect of combined curcumin and IR on animal survival. Animals were removed from the study and euthanized when their body mass decreased by > 20% based on their weight at beginning of experiment. There was a statistical difference in mean survival between the curcumin alone or IR alone-treated groups when compared with the untreated animals (*p = 0.05). The difference in mean survival between the combined treatments group and all other groups was highly significant (**p = 0.0001). Notably, 3 animals from the combined treatment group survived beyond the last data point collected at day 90.

References

    1. Hunter KD, Parkinson EK, Harrison PR. . Profiling early head and neck cancer. Nat Rev Cancer 2005; 5:127 - 35; http://dx.doi.org/10.1038/nrc1549; PMID: 15685196 - DOI - PubMed
    1. Leemans CR, Braakhuis BJM, Brakenhoff RH. . The molecular biology of head and neck cancer. Nat Rev Cancer 2011; 11:9 - 22; http://dx.doi.org/10.1038/nrc2982; PMID: 21160525 - DOI - PubMed
    1. Marur S, D’Souza G, Westra WH, Forastiere AA. . HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010; 11:781 - 9; http://dx.doi.org/10.1016/S1470-2045(10)70017-6; PMID: 20451455 - DOI - PMC - PubMed
    1. Gillison ML. . Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 2004; 31:744 - 54; http://dx.doi.org/10.1053/j.seminoncol.2004.09.011; PMID: 15599852 - DOI - PubMed
    1. Hobbs CGL, Sterne JAC, Bailey M, Heyderman RS, Birchall MA, Thomas SJ. . Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin Otolaryngol 2006; 31:259 - 66; http://dx.doi.org/10.1111/j.1749-4486.2006.01246.x; PMID: 16911640 - DOI - PubMed

MeSH terms